Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026Frontiers in EndocrinologyOpen Access

Glucagon-like peptide-1 receptor agonists and the risk of Parkinson’s disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data

View Full Paper
Ask AI
Bookmark
Share

Key result

GLP-1RAs are linked to a ~32% lower risk of incident Parkinson's disease in T2D.

  • HR 0.68
  • 95% CI 0.54-0.85
  • P=0.001
  • n=452,763

Why the study?

Real-world evidence on the association between GLP-1RA use and Parkinson's disease risk in patients with type 2 diabetes remains inconsistent and has not been systematically synthesized.

Does GLP-1RA exposure reduce the risk of Parkinson's disease in patients with type 2 diabetes?

Population

452,763 participants across six studies of patients with T2DM

Comparison

GLP-1RA exposure vs DPP-4 inhibitors, metformin, and other hypoglycemic drugs

Design

Systematic review and meta-analysis of cohort and case-control studies

Authors

YCYing ChenXWXueping WangJWJingjuan Wang

Discussion

Loading...

Member takes

Overview

May support GLP-1RA investigation for PD prevention in T2D; leaves open causal confirmation in RCTs.

Study Design

Type

Meta-Analysis (n=452,763)

Multicenter

Yes

Structured PICO

Does GLP-1RA exposure reduce the risk of Parkinson's disease in patients with type 2 diabetes?

P
Population
452,763 patients with type 2 diabetes from six observational studies, followed for 1.54 to 20 years to evaluate the association between GLP-1RA exposure and incident Parkinson's disease.
E
Exposure
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a class
C
Comparator
Other hypoglycemic drugs (including dipeptidyl peptidase-4 [DPP-4] inhibitors and metformin)
O
Outcome
Risk of incident Parkinson's disease (PD)hard clinical

Main Result

Hazard Ratio: 0.68 (95% CI 0.54–0.85)

p-value: p=0.001

In a meta-analysis of real-world data, GLP-1RA use in patients with type 2 diabetes was associated with a significantly reduced risk of developing Parkinson's disease compared to other hypoglycemic agents.

Limitations

  • Observational design of included studies with potential for residual confounding and indication bias
  • Significant between-study heterogeneity (I² = 67.6%)
  • Participants were exclusively patients with T2DM, limiting generalizability to nondiabetic populations
  • Modest sample sizes in some studies and lack of subgroup analyses by individual GLP-1RA agents
  • Protocol was not prospectively registered
  • inherent limitations to observational study designs
  • possibility of residual confounding

Cite This Study

Chen et al. (2026) conducted a meta-analysis in Type 2 diabetes mellitus (n=452,763). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) vs. Other glucose-lowering drugs or no GLP-1RA was evaluated on Incident Parkinson's disease (HR 0.68, 95% CI 0.54-0.85, p=0.001). GLP-1RA exposure was significantly associated with a 32% reduced risk of incident Parkinson's disease (HR 0.68) in patients with type 2 diabetes.

synapsesocial.com/papers/6aa74d4352fe9df4fa1122e4https://doi.org/10.3389/fendo.2026.1849318
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis2026 · 1 citations
  2. 2GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential2025 · 28 citations
  3. 3Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson’s disease2026 · 5 citations
  4. 4Burden of non-motor symptoms of Parkinson’s disease: cost-of-illness and quality-of-life estimates through a scoping review2024 · 9 citations
  5. 5Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists2009 · 17 citations